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Resistance to second- and third-generation 
cephalosporins among Escherichia coli and Klebsiella 
species is rare in Finland 
Raija Manninen ' j 2 ,  Helena Auvinen3, Pentti Huovinen', and the Finnish Study 
Group for Antimicrobial Resistance (FiRe)* 
'Antimicrobial Research Laboratory, National Public Health Institute, Turku, 2Department of Medical 
Microbiology, Turku University, Turku, and 3Kanta-Hame Central Hospital, Hameenlinna, Finland 
Objective: To investigate the antimicrobial resistance of Escherichia coli and Klebsiella spp. from pus, urine and 
respiratory specimens, with particular emphasis on the detection of third-generation cephalosporin resistance. 
Methods: E. coli (698) and Klebsiella sp. (476) strains from pus, respiratory and urinary specimens from hospital 
patients were collected from 19 laboratories. Data about consumption of third-generation cephalosporins and 
cefuroxime were collected from 24 hospitals. Antimicrobial susceptibility was tested with disk diffusion in primary 
laboratories and by an agar dilution method. Extended-spectrum p-lactarnase (ESBL) production was studied with a 
double disk synergy test and an ESBL Etest. The P-lactamase classes were characterized with polymerase chain reaction 
probes of the TEM and SHV p-lactamase families and isoelectric focusing. 
Results: Only 0.6% of E. coliand 2.3% of Klebsiella spp. strains were resistant or intermediately resistant t o  cefotaxime, 
ceftriaxone and/or ceftazidime. The ESBL producers detected comprised one E. coli harboring TEM-like genes and five 
Klebsiella pneumoniae strains, two of which harbored SHV-like genes, two TEM-like genes and one both. Although 
consumption of cefuroxirne has increased in the years 1990-1994, from 3.48 to  5.84 defined daily doses/100 bed-days, 
and the consumption of third-generation cephalosporins from 1.25 to 1.94 defined daily doses/100 bed-days, cefuroxime 
resistance of E. coli was only 3%. 
Conclusion: Although the use of broad-spectrum cephalosporins has increased, resistance to  second- and third- 
generation cephalosporins is still rare in Finland. 
Key words: E .  coli, Klebsiella spp., extended-spectrum P-lactamases, third-generation cephalosporins, cefuroxime, 
TEM, SHV, cephalosporin consumption 
INTRODUCTION 
Numerous extended-spectrum P-lactamases (ESBLs) 
cause resistance to cefiazidime, cefiriaxone, cefotaxime 
and other newer cephalosporins, as well as ampicillin 
and first-generation cephalosporins [ 11. The ESBL 
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enzymes are most often altered derivatives of P- 
lactaniases from the TEM or SHV groups. In addition 
to P-lactaniase production, decreased permeability 
dependent on outer membrane porins plays a role in 
resistance [2].  Unfortunately, strains producing ESBLs 
are not always detected by disk diffusion susceptibility 
tests, because the existing breakpoints classify sonie of 
them as intermediate or even susceptible [3]. Third- 
generation cephalosporins may be less effective in the 
treatment of serious infections due to ESBL-producing 
Gram-negative bacilli, although standard-inoculuni 
iiiininial inhibitory concentrations (MIC) are within 
the susceptible range [4]. 
In 1991 we studied the resistance of blood culture 
isolates of Esdzerichiu coli and Klebsiella spp., but ESBL 
enzymes were not found [S]. In the present study, we 
investigated antirnicrobial resistance of E. coli and 
Klehsiellu spp. from pus, urine and respiratory speci- 
mens, with particular emphasis on the detection of 
third-generation cephalosporin resistance. We also 
report the consumption of cefuroxiine and third- 
generation cephalosporins in 1984-94. 
MATERIALS AND METHODS 
Bacteria 
A total of 698 E. mli and 476 Klebsiellu spp. strains were 
collected from 19 clinical microbiology laboratories 
distributed throughout Finland. The collection was 
performed in 1994 from February to Ilecember. From 
each laboratory 15 consecutive E.  coli strains and 10 
Klebsiellu spp. strains from pus, urine and respiratory 
samples of hospital patients were requested, 75 in all. 
Of  the received E.  coli strains, 292 were isolated from 
pus, 278 from urine, and 128 from respiratory speci- 
mens. Correspondingly, 180, 193 and 103 Klehsicllu 
spp. strains were obtained. The strains showing synergy 
in the double disk test (see below) were identified with 
API 20E (bioMtrieux, Marcy-l'Etoik, France). The 
chi-square test was used for coniparing the rates of 
susceptibility in the various specimen types. 
Susceptibility determination 
The MICs of antimicrobial agents liiited below were 
determined in the National Public Health Institute by 
an agar plate dilution niethod following standard 
procedures of the National Committee for Clinical 
Laboratory Standards (NCCLS) [6]. Antimicrobials 
tested (and their respective sources) were: ampicillin 
(MIC range 0.06-64 pg/niL), piperacillin (0.06- 
64 pg/mL), cephalothin (0.125-64 pg/mL), cefu- 
roxime sodium (0.06-16 pg/mL), cefotaxime (0.016- 
16 pg/mL), ceftriaxone (0.036-32 pg/niL), gentamkin 
(0.016-16 pg/mL), tobraniycin (0.01 6-1 6 pg/mL), 
airiikacin (0.016-1 6 pg/niL), ciprofloxacin (0.004- 
2 pg/iiiL), chloraniphenicol (0.06-64 pg/niL), tri- 
niethopriin (0.016-16 pg/niL) and tetracycline (0.06- 
32 pg/niL) (all from Sigma), anioxicillin (Sigma) 
combined with clavulanate (0.06/0.032-16/8 pg/mL) 
(SniithKline Beechani Pharniaceuticals), aztreonam 
(0.01 6-1 6 pg/mL) (Squibb), ceftazidinie (0.016- 
16 pg/niL) (Glaxo), imipenein (0.01 6-1 6 pg/iiiL) 
(Merck Sharp & Dohnie), netilniicin (0.016- 
16 pg/niL) (Schering), ofloxacin (0.004-2 pg/niL) 
(Hoechst) and piperacillin combined with tazobactani 
(0.016/4-32/4 pg/mL) (Lederle). Inoculated I3BL 
Mueller-Hinton I1 agar (Becton Ilickinson Micro- 
biolog7 Systems, Cockeysville, USA) plates were in- 
cubated overnight at 35°C. Control strains E. coli 
ATCC 25922 and ATCC 3521 8, Stupliyloroccus aureus 
ATCC 29213, Etztevococcrir fuecalis ATCC 2921 2 and 
Psecrdovnorzus ueriqitzosn ATCC 27853 were tested on 
each plate lot. 
Disk diffusion susceptibility tests for cefuroxime, 
cefotaxime, ceftazidime, ceftriaxone and aztreonaiii 
were performed and zone diameters measured in 
each laboratory. The disk diflusion methods were 
those routinely used in each laboratory. Neo-Sensitabs" 
tablets (Kosco, Taastrup, Denmark) were used in 
12 laboratories, Biodisk disks (Ab Biodisk, Solna, 
Sweden) in three laboratories and Oxoid disks 
(Unipath Ltd, Basingstoke, UK) in three laboratories. 
In one laboratory, the assignment to susceptible, inter- 
mediate or resistant categories was made by a n  
automated analyzer (Vitek, bioMtrieux, Marcy- 
l'Etoile, France). The breakpoints and inoculuni used 
were those recommended either by the NCCLS or by 
the Swedish Reference Group for Antibiotics (SRGA), 
according to the guidelines of the disk manufacturers. 
Tests for extended-spectrum P-lactamases 
MIC results and inhibition zones of each laboratory 
were plotted as histogranis with inhibition zone 
millimeters or MIC values on the x-axis and percentage 
strains on the y-axis, with a WHONET3 computer 
program 171. The strains deviating from the main 
population were selected for further investigation. The 
Neo-Sensitabs double disk synerby test and ESBL Etest 
(Ab Biodisk, Solna, Sweden), were carried out on 23 
E. coli and 74 Klebsiellu isolates on the basis of increased 
MIC values: ceftriaxone 20.25 pg/iiiL, cefotaxinie 
20.5 pg/mL or ceftazidime 21 pg/niL. Double disk 
tests were also performed on an additional 29 Klebsiella 
and 14 E. coli strains that had smaller inhibition zones 
than the susceptible main population in the inhibition 
zone histograms of these three antimicrobials. The 
ESBL Etest contains decreasing gradients of ceftazidiine 
and ceftazidinie + clavulanic acid in the same strip. 
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According to the package supplement, the strain may 
produce ESBL if the ratio between ceftazidime MIC 
and ceftazidime + clavulanic acid MIC is 21 6. A double 
disk test was performed, placing tablets containing 
ceftazidime (30 pg) and cefotaxime (30 pg) at a distance 
of 3 cm from center to center from a tablet containing 
amoxycillin+clavulanate (30+15 pg) [8] .  Extension of 
the zone of inhibition towards the tablet contain- 
ing amoxycillin+clavulanate suggests the presence of 
ESBL. Because the zones were generally over 30 mm, 
the test was repeated increasing the distance to 4 cm 
and adding aztreonam (30 pg) and ceftriaxone (30 pg) 
tablets. 
P-Lactamase isoelectric focusing and PCR 
The P-lactamase classes were determined for the strains 
showing synergy in the double disk test. Analytic 
isoelectric focusing of crude P-lactaniase extracts 
obtained from ultrasonically distrupted cells was per- 
formed in polyacrylamide gels as described previously 
[9]. The polymerase chain reaction (PCR) was carried 
out using previously described amplification primer 
pairs for detecting SHV-like [lo] and TEM-like genes 
[ l l ] .  As controls were used a TEM-1 and a SHV-1- 
producing strain and six E.coli and seven Klebsiella spp. 
ampicillin-resistant strains without increased resist- 
ance to third generation cephalosporins. An HB-TR1 
(Hybaid Ltd, Middlesex, UK) thermocycler was used. 
The 100-pL reaction volume contained 10 pL DNA 
template and 90 pL reaction mixture, which consisted 
of 20 pmol of each primer, 1 U DynaZyme polymerase 
(Finnzymes Oy, Espoo, Finland), 1 pL DNA poly- 
merization niix (Pharmacia Biotech, USA) and 10 pL 
DynaZyme buffer. The TEM was amplified by 35 
cycles of denaturation at 94°C for 30 s, annealing at 
55°C for 1 min and extension at 72°C for 1 min. The 
SHV was detected by 30 cycles of denaturation at 94°C 
for 2 min, annealing at 60°C for 1 min and extension 
at 72°C for 2 min. The PCR products were analyzed 
by electrophoresis in 1.5% agarose gels. The patterns 
were stained with ethidium bromide, photographed 
under UV-light and compared with a 100-bp ladder. 
Cephalosporin consumption 
Third-generation cephalosporin consumption data in 
1994 were collected from the hospital pharmacies of 24 
hospitals and calculated in defined daily doses (DDD) 
per 100 bed-days. One  DDD was defined as 6 g cefo- 
taxime, 2 g ceftriaxone, 4 g ceftizoxime, 6 g ceftazidime, 
0.4 g cefixime, 4 g cefepime and 4 g cefpirome [12]. 
The data were compared to consumption rates in the 
previous survey [5]. 
RESULTS 
Susceptibility to antimicrobials 
One E. coli isolate was resistant to ceftazidime and 
in addition to this, three isolates had intermediate 
MIC values (Table 1). Resistance to the third-genera- 
tion cephalosporins cefotaxime, cefiriaxone and/or 
cefiazidime was seen in 6 of 476 (1.3%) Klebsiella spp. 
isolates, and intermediate resistance in five isolates 
Table 1 Antimicrobial susceptibility of 698 E. coli strains collected from pus, urinary and respiratory samples from 19 
laboratories 
Breakpoints 
W m L )  Interpretation (%) MIC (pg/mL) 
No. of 
Antibiotic isolates S1  Rt R I Range MICso MICyo 
Ampicillin 
Piperacillin 
Amoxicillin/clavulanic acid 
Piperacillin/tazobactam 
Cephalothin 
Cefuroxime 
Cefotaxime 
Ceftriaxone 
Ceftazidime 
Imipenem 
Aztreonam 
Gentamicin 
Ciprofloxacin 
Chloramphenicol 
Trimethoprim 
Tetracycline 
698 
698 
614 
695 
698 
698 
698 
697 
698 
698 
698 
698 
698 
698 
698 
698 
8 32 
16 128 
814 32/16 
l6/4 128/4 
8 32 
8 32 
8 64 
8 64 
8 32 
4 16 
8 32 
4 16 
1 4 
8 32 
8 16 
4 16 
22.6 1.6 
5.3 11.0 
3.9 15.5 
0 0.6 
8.0 9.7 
3.4 2.9 
0 0 
0 0 
0.1 0.4 
0 0.1 
0 0.1 
0.1 0 
0.3 0.7 
6.7 6.6 
14.9 0 
17.6 0.4 
0.5 to >64 
10.6 to >64 
0.5/0.25 to >16/8 
0.32/4 to >32/4 
1 to >64 
0.25 to >16 
10.016 to 4 
20.016 to 4 
0.032 to >16 
0.06 to 8 
10.16 to 16 
0.125 to 16 
10.004 to >4 
1 to 264 
0.06 to >16 
0.5 to >32 
4 
2 
8/4 
4/4 
8 
4 
0.064 
0.064 
0.25 
0.25 
0.064 
0.5 
0.016 
8 
0.5 
2 
>64 
64 
l6/8 
414 
16 
8 
0.125 
0.064 
0.25 
0.5 
0.125 
1 
0.032 
16 
16 
>32 
S=susceptible, I=intermediate, R=resistant. 
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Table 2 Antimicrobial susceptibility of 476 Klebriella spp. strains collected from pus, urinary and respiratory samples from 19 
laboratories 
Breakpoints 
(i4dmL) Interpretation (“A) MIC (pg/iiiL) 
No. of -~ 
Antibiotic isolates S< K2 R 1 Kange MICiii MIC,w 
~~ ______ 
Aiiipicilliii 
Piperacilliri 
Aiiipicillin/clavulanic acid 
Piperacillin/tazobactaiii 
Cephalothin 
Cefuroxiine 
C efo taxime 
Ceftriaxone 
Ceftazidime 
Inlipenem 
Aztreonam 
Gentamicin 
Ciprofloxacin 
Chloramphenicol 
Triniethoprini 
Tetracycline 
~ 
476 
476 
41 1 
475 
476 
476 
476 
476 
476 
476 
476 
475 
476 
476 
476 
476 
8 32 84.0 
16 128 6.5 
8/4 32/16 4.9 
16/4 128/4 0 
8 32 11.3 
8 32 7.8 
8 64 0 
8 64 0.2 
8 32 1.3 
4 16 0 
8 32 1.9 
4 16 1.1 
1 4 1.9 
8 32 17.9 
8 16 20.6 
4 16 10.9 
12.4 
4.2 
5.1 
2.9 
8.b 
9.9 
0.6 
1.7 
0.4 
0.2 
0.4 
0.2 
0.6 
3.8 
0 
3.8 
1 to >64 
0.25 to >64 
0.5/0.25 to >16/8 
0.125/4 to >32/4 
0.5 to >64 
0.25 to >16 
10.016 to > I 6  
50.016 to >32 
0.032 to >16 
0.06 to 8 
C0.016 to >16 
0.032 to 216 
0.008 to >2 
2 to >64 
0.032 to > I 6  
0.5 to 232 
64 
8 
4/2 
414 
4 
4 
0.064 
0.064 
0.25 
0.25 
0.064 
0.5 
0.032 
8 
1 
2 
>64 
32 
8/4 
8/4 
32 
16 
0.25 
0.25 
0.5 
0.5 
0.25 
1 
0.25 
64 
32 
16 
S=susceptible, I=interniediate, R=resistant. 
(1.1%) (Table 2). Five ofthese 11 Klebsiellu isolates were 
resistant to one or more aminoglycosides. 
When isolates of pus, urinary and respiratory 
saniples were compared, some difference in suscepti- 
bility rates to other antimicrobials were observed. For 
E.  coli, susceptibility to trimethoprim was 79% among 
urinary isolates and 92% among respiratory isolates 
(p<O.OOI). Susceptibility to cefuroxime was 89% among 
respiratory isolates and 96% among urinary isolates 
( ~ 4 . 0 1 5 ) .  With piperacillin-tazobactam, pus isolates 
were most susceptible, at 88% (p=Q.O11). Among 
Klebsiella isolates, susceptibility to trimethoprim among 
urinary isolates was lowest again, at 69%, compared 
with 91% of respiratory isolates (p<0.001). The corres- 
ponding figures for chloramphenicol were 71% among 
urinary and 84% among respiratory isolates (p=0.003). 
ESBL-producing strains 
One E. roli strain and nine Klebriellu spp. strains showed 
synergy around a third-generation cephalosporin disk 
in the double disk test, which suggests ESBL pro- 
duction (Table 3). The strains originated from six 
respiratory and four pus samples from six laboratories. 
Ceftazidinie MIC values were most often increased, 
while ceftriaxone was most often affected in the disk 
diffusion test. Increasing the distance between the disks 
in the double disk test from 3 cm to 4 cm gave no new 
strains in addition to these. Double disk synergy was 
not seen among the 29 strains that were selected solely 
on the basis of slightly reduced zones in the disk 
diffusion tests in the primary laboratory without at least 
slightly increased MIC values for any third-generation 
cephalosporin. Four ESBL producers were detected 
with the ESBL Etest. 
TEM-homologous genes occurred in three of the 
ESBL-producing strains, SHV-homologous genes in 
two cases and both TEM and SHV genes in one strain 
(Table 3). Four K. oxytoca strains showed neither TEM- 
nor SHV-homologous genes by PCR studies; thus 
these strains may produce chromosomal types of 
P-lactamases [I] Thirteen ampicillin-resistant (MIC 
21 6 pg/mL) strains without reduced susceptibility to 
extended-spectrum cephalosporins were studied as 
controls; of the six E. coli strains studied, five hybridized 
with TEM probes and one both with TEM and SHV 
probes; of the seven K. pneumoniac strains, four had 
SHV-, two had TEM- and one had both SHV- and 
TEM-homologous genes according to PCR.  
Consumption of broad-spectrum cephalosporins 
The total consumption of third-generation cephalo- 
sporins had increased from the previous study in 24 
hospitals from 1.25 DDD/100 bed-days in 1990 to 1.94 
DDD/100 bed-days in 1994 (Figure 1). Ceftriaxone 
was used most at 1.25 DDD/lOO bed-days, followed by 
ceftazidime 0.34, ceftizoxime 0.17 and cefotaxime 0.16 
DDD/100 bed-days. During the same period, the 
consumption of cefuroxime had increased from 3.48 
DDD/bed-days to 5.84 DDD/100 bed-days. 
DISCUSSION 
Resistance to third-generation cephalosporins still seems 
to be rare in Finland. TEM- or SHV-derived ESBLs 
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Table 3 Resistance of the strains showing synergy in the double disk test. MICs were determined with agar plate ddution in 
the National Public Health Institute and disk diffusion tests were performed in primary laboratories. The four first strains 
produced an extended-spectrum b-lactamase according to the ESBL Etest 
Cefuroxime Cefotaxime Ceftriaxone Ceftazidime Aztreonam P C R  result 
Labo- MIC MIC MIC MIC MIC SHV or 
Species ratory (pg/mL) Disk (pg/mL) Disk (pg/mL) Disk (pg/mL) Disk (pg/mL) Disk TEM PI 
E. coli G 8 S S 0.5 S S 0.5 S S >16 R S 1 S S TEM 5.6 
K.pneumoniae 0 >16 R R 8 S R 16 I R >16 R R >16 R R TEM+ 5.7, 
SHV 7.0 
K.pneurnouiae C >16 R R 8 S R 16 I I >16 R R >I6 R R TEM 5.6 
K.pneumoniae C 16 I R 8 S R 16 I R >16 R R >I6 R R TEM 5.4 
K.  oxytoca C >16 R R 1 S S 8 S I >16 R R 16 I I Other 7.7 
K.  pneumoniae" B 16 I R 0.25 S S 0.25 S S 1 S S 0.25 S S SHV 7.6 
K.  pneumoniae B 16 I I 4 S I 4 S I 16 I S 2 S S SHV 7.6 
K.  oxytoca P > 1 6 R R  2 S 1 8 s  I 1 S S >16 R R Other 5.3 
K.  oxytoca F 216 R S 0.25 S S 1 S S 0.12 s s 2 S S Other 7.3 
K.  ocytoca G > 1 6 R R  1 S S 16 I I 1 S S >16 R R Other 5.3, 
5.7 
S=susceptible, I=intermediate, R=resistant. 
"The strain was isolated from both respiratory and pus samples from the same patient. 
DDDll 00 # 3rd-generation 
bed-days cephalosporins 
6 Cefuroxime 
5 
4 
3 
2 
1 
0 
1984 1985 1986 1987 1988 1989 1990 1994Year 
Figure 1 Consumption of cefuroxime and third- 
generation cephalosporins in 24 Finnish hospitals. 
DDDZdefined daily dose. 
were produced by one E. coli strain (0.1%) and five K. 
pneumoniae strains (1.1%). In a multicenter survey by 
the European Study Group on Antibiotic Resistance, 
4% of E. coli and 7% of Klebsiella septicemia isolates 
already showed reduced susceptibility or resistance to 
cefotaxime, ceftazidime and/or aztreonam in 1987-88 
[13]. In French hospitals in 1991, ESBLproduction was 
present in 9.6% of K. pneumoniae, 1.9% of K. oxytoca 
and 0.03% of E. coli [14]. 
In our 1991 blood isolate collection of 566 E. coli 
strains and 108 Klebsiellu spp. strains, ESBL strains were 
not found, and 1% intermediate resistance of Klebsiella 
spp. to ceftazidime represented all of the resistance to 
third-generation cephalosporins [5]. The specimen 
types are different and hence not wholly comparable, 
but it seems that the cephalosporin susceptibility of 
Klebsiella spp. has decreased slightly. The susceptibility 
to cephalothin was 88% in 1991, while it is now 
80% among pus, urinary and respiratory isolates. The 
susceptibility to cefuroxime in the previous study was 
91%, while in this study it was 82%. Interestingly, the 
cefuroxime susceptibility of E. coli did not seem to 
decrease, despite the increasing use of cefuroxime; the 
susceptibility was 96% in 1991 and 94% in this study. 
Consumption of the third-generation cepahalo- 
sporins was increased 1.5-fold and consumption of 
the second-generation cephalosporin cefuroxime 1.7- 
fold in 1994 as compared to 1990. Cefuroxime was 
clearly used more; the consumption of third-generation 
cephalosporins was only one-third of the cehroxime 
consumption. In the six hospitals where ESBL strains 
were found, the consumption of third-generation 
cephalosporins was on average higher, 2.6 DDD/100 
bed-days, compared to 1.7 DDD/100 bed-days in 
other hospitals which submitted strains. The 4-year 
period is too short for conclusions to be drawn, but 
it seems that the bacterial population tolerates a 
limited use of third-generation cephalosporins for 
life-threatening infections without producing resistant 
mutants. 
The resistance to other studied antimicrobials, 
aminoglycosides and fluoroquinolones, was low, and 
the resistance rates were similar to those in the 1991 
study. When the resistance rates of pus, urinary and 
respiratory isolates were compared, cefuroxime resist- 
ance and ESBL production were more common among 
the respiratory and pus infections than in the probably 
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less complicated urinary infections. Urinary isolates 
were predictably more resistant to trimethoprim. 
Clinical laboratories should be able to detect 
reduced susceptibility in time to contribute to anti- 
microbial treatment and infection control decision- 
making. The ESBL-producing strains did not always 
reach the breakpoints of resistance, even when zone 
diameters of extended-spectrum cephalosporins were 
diminished and MICs were increased. An ideal way of 
detecting bacterial ESBLs in hospital laboratories has 
not been discovered yet. The classical test method for 
ESBL production is the double disk synergy test. The 
double disk test has proved to be problematic because 
of the difficulty of optimal spacing of the disks [15]. It 
does not work if inhibition zones are very small or 
absent, or large and close to the susceptible dimensions. 
We had to repeat the tests with a greater distance 
between the disks because the zones overlapped. 
Repeating tests on clinical specimens leads to delayed 
susceptibility results. Some of the strains showing 
synergy in the double disk test were K. oxytocu strains 
hyperproducing chromosomally mediated group 2be 
P-lactamases, which hydrolyze cefotaxime and aztreo- 
nam and are inhibited by clavulanic acid [l]. The ESBL 
Etest detects enzymes regardless of zone diameter. The 
ESBL Etest used functions properly only if the enzyme 
causes high resistance to ceftazidime, and the resistance 
is inhibited by clavulanic acid. Ceftazidime may be the 
best single test antibiotic for detecting ESBLs, although 
breakpoints for resistance were not always reached [3] .  
P-Lactamase inhibitors cannot always restore suscepti- 
bility to p-lactams if the strain hyperproduces an in- 
hibitor-susceptible enzyme [2]. 
Strains producing ESBLs were not resistant to 
all extended-spectrum p-lactams. This underlines the 
importance of performing specific susceptibility tests 
for each antimicrobial agent used in the hospital instead 
of using only a representative of the third-generation 
cephalosporins, at least when inhibition zones are 
reduced. The disk diffusion method proved to be 
comparable to MIC determinations indicating reduced 
susceptibility. 
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